Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4087888 | 0.90 | HSD17B10 (0.47) | HSD17B10ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL283443 | 0.86 | NR1H2 (0.45) | HSD17B10NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL71904 | 0.86 | NR1H2 (0.45) | HSD17B10NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL71903 | 0.86 | NR1H2 (0.45) | HSD17B10NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL5005297 | 0.83 | ATM (0.46) | HSD17B10NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL7411944 | 0.83 | ATM (0.46) | HSD17B10NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL3850660 | 0.83 | ATM (0.46) | HSD17B10NR1H2CHRM2CHRM1CHRM3 | |
| SCHEMBL24121385 | 0.83 | ATM (0.42) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL8073389 | 0.83 | HSD17B10 (0.41) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL19158003 | 0.83 | ATM (0.42) | HSD17B10CHRM2CHRM1CHRM3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | Clear Creek Bio, Inc. (US) | 2025-01-23 | — | — | US | disclosed |
| WO-2023064493-A1 | COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES | Clear Creek Bio, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250025443-A1 | COMPOUNDS AND METHODS FOR TREATING CORONA VIRUSES | ACE, PREP, PEPD | HSD17B10 2712/4885NR1H2 3333/4885CHRM2 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.